

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: - Bio-Gene Technology Limited
ABN: 32 071 735 950

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Timothy Grogan
Date of last notice	21 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Grogan Pty Ltd <Grogan Family A/C>. (Director is a beneficiary of the Trust)
Date of change	10 August 2026
No. of securities held prior to change Grogan Pty Ltd <Grogan Family A/C>	276,916 Ordinary Shares 108,696 Unlisted Options (\$0.034 @ 15-May-28) 108,696 Unlisted Options (\$0.046 @ 15-May-30)
Class	Ordinary shares Unlisted Options (\$0.035 @ 15-Oct-27)
Number acquired	200,000 Ordinary Shares 100,000 Unlisted Options (\$0.035 @ 15-Oct-27)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change Grogan Pty Ltd <Grogan Family A/C>	476,916 Ordinary Shares 100,000 Unlisted Options (\$0.035 @ 15-Oct-27) 108,696 Unlisted Options (\$0.034 @ 15-May-28) 108,696 Unlisted Options (\$0.046 @ 15-May-30)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	200,000 ordinary shares subscribed for under the Placement announced 26 May 2026 and approved by shareholders at the EGM held on 5 August 2026. 100,000 unlisted options approved by shareholders at the EGM held on 5 August 2026.

Part 2 – Change of director's interests in contracts N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: - Bio-Gene Technology Limited
ABN: 32 071 735 950

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrew Guthrie
Date of last notice	21 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Anker Super Fund Pty Ltd <Kerand Super A/C>. (Director is a member of the Superannuation Fund)
Date of change	10 August 2026
No. of securities held prior to change Anker Super Fund Pty Ltd <Kerand Super A/C>	484,784 Ordinary Shares 108,696 Unlisted Options (\$0.034 @ 15-May-28) 108,696 Unlisted Options (\$0.046 @ 15-May-30)
Class	Ordinary shares Unlisted Options (\$0.035 @ 15-Oct-27)
Number acquired	200,000 Ordinary Shares 100,000 Unlisted Options (\$0.035 @ 15-Oct-27)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change Anker Super Fund Pty Ltd <Kerand Super A/C>	684,784 Ordinary Shares 100,000 Unlisted Options (\$0.035 @ 15-Oct-27) 108,696 Unlisted Options (\$0.034 @ 15-May-28) 108,696 Unlisted Options (\$0.046 @ 15-May-30)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	200,000 ordinary shares subscribed for under the Placement announced 26 May 2026 and approved by shareholders at the EGM held on 5 August 2026. 100,000 unlisted options approved by shareholders at the EGM held on 5 August 2026.

Part 2 – Change of director's interests in contracts N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: - Bio-Gene Technology Limited
ABN: 32 071 735 950

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter May
Date of last notice	21 July 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Peter Donald and Sondra May <May Superannuation A/C> (Director is a member of the Superannuation Fund)
Date of change	10 August 2026
No. of securities held prior to change Peter May Peter Donald and Sondra May <May Superannuation A/C>	1,375,076 Ordinary Shares 684,521 Ordinary Shares 108,696 Unlisted Options (\$0.034 @ 15-May-28) 108,696 Unlisted Options (\$0.046 @ 15-May-30)
Class	Ordinary shares Unlisted Options (\$0.035 @ 15-Oct-27)
Number acquired	200,000 Ordinary Shares 100,000 Unlisted Options (\$0.035 @ 15-Oct-27)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change Peter May Peter Donald and Sondra May <May Superannuation A/C>	1,375,076 Ordinary Shares 884,521 Ordinary Shares 100,000 Unlisted Options (\$0.035 @ 15-Oct-27) 108,696 Unlisted Options (\$0.034 @ 15-May-28) 108,696 Unlisted Options (\$0.046 @ 15-May-30)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	200,000 ordinary shares subscribed for under the Placement announced 26 May 2026 and approved by shareholders at the EGM held on 5 August 2026. 100,000 unlisted options approved by shareholders at the EGM held on 5 August 2026.

Part 2 – Change of director's interests in contracts N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: - Bio-Gene Technology Limited
ABN: 32 071 735 950

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Ramsey
Date of last notice	23 November 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Yoorala Holdings Pty Ltd <Ramsey Superannuation A/C> (Director is a member of the Superannuation Fund)
Date of change	10 August 2026
No. of securities held prior to change Yoorala Holdings Pty Ltd <Ramsey Superannuation A/C>	119,000 Ordinary Shares
Class	Ordinary shares Unlisted Options (\$0.035 @ 15-Oct-27)
Number acquired	200,000 Ordinary Shares 100,000 Unlisted Options (\$0.035 @ 15-Oct-27)
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change Yoorala Holdings Pty Ltd <Ramsey Superannuation A/C>	319,000 Ordinary Shares 100,000 Unlisted Options (\$0.035 @ 15-Oct-27)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	200,000 ordinary shares subscribed for under the Placement announced 26 May 2026 and approved by shareholders at the EGM held on 5 August 2026. 100,000 unlisted options approved by shareholders at the EGM held on 5 August 2026.

Part 2 – Change of director's interests in contracts N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Drew Speedy
Company Secretary
10 August 2026

⁺ See chapter 19 for defined terms.